Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis

The multiple sclerosis (MS) treatment landscape in the United States has changed dramatically over the past decade. While many disease-modifying therapies (DMTs) have been approved by the US Food and Drug Administration (FDA) for the treatment of relapsing forms of MS, DMT costs continue to rise. Th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Pharm Pract
Hauptverfasser: Bell, Christine, Anderson, James, Ganguly, Tanmoy, Prescott, James, Capila, Ishan, Lansing, Jonathan C., Sachleben, Richard, Iyer, Mani, Fier, Ian, Roach, James, Storey, Kristina, Miller, Paul, Hall, Steven, Kantor, Daniel, Greenberg, Benjamin M., Nair, Kavita, Glajch, Joseph
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2017
Schlagworte:
Review Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144347/
https://ncbi.nlm.nih.gov/pubmed/28847230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0897190017725984
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge